The elastin connection and melanoma progression

Anticancer Research

Volumn 25, Issue 4, 2005, Pages 2617-2626

  Hornebeck, William ^a   Robinet, Arnaud ^a   Duca, Laurent ^a   Antonicelli, Frank ^a   Wallach, Jean ^b   Bellon, Georges ^a  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

Elastin; Galectin 3; Matrikines; Melanoma; Review

Indexed keywords

COLLAGEN TYPE 1; CYTOKINE; ELASTASE; ELASTIN; ELASTIN RECEPTOR; ELASTOKINE; GALECTIN 3; INTERSTITIAL COLLAGENASE; MATRIGEL; MATRIX METALLOPROTEINASE 14; RECEPTOR; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; CANCER GROWTH; CANCER INVASION; CELL ACTIVATION; CONSENSUS SEQUENCE; ELASTIC FIBER; ELASTOLYSIS; ENZYME ACTIVATION; ENZYME SYNTHESIS; HUMAN; IN VITRO STUDY; MELANOMA; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVIEW;

AMINO ACID SEQUENCE; DISEASE PROGRESSION; ELASTIN; HUMANS; MATRIX METALLOPROTEINASES; MELANOMA; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; RECEPTORS, CELL SURFACE;

EID: 22944452122     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH and Morabito A: Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19: 3622-3634, 2001.
2. Labrousse AL, Ntayi C, Hornebeck W and Bernard P: Stromal reaction in cutaneous melanoma. Crit Rev Oncol Hematol 49: 269-275, 2004.
3. Albino AP, Reed JA and McNutt NS: Molecular Biology of Cutaneous Malignant Melanoma. 5th ed. Philadelphia: Lippencott-Raven, 1997.
4. Ruiter D, Bogenrieder T, Elder D and Herlyn M: Melanomastroma interactions: structural and functional aspects. Lancet Oncol 3: 35-43, 2002.
5. Quaranta V: Motility cues in the tumour microenvironment. Differentiation 70: 590-598, 2002.
6. Schenk S and Quaranta V: Tales from the crypt[ic] sites of the extracellular matrix. Trends Cell Biol 13: 366-375, 2003.
7. Ortega N and Werb Z: New functional roles for non-collagenous domains of basement membrane collagens. J Cell Sci 115: 4201-4214, 2002.
8. Mott JD and Werb Z: Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 16: 558-564, 2004.
9. Hornebeck W, Emonard H, Monboisse JC and Bellon G: Matrix-directed regulation of pericellular proteolysis and tumour progression. Semin Cancer Biol 12: 231-241, 2002.
10. Maquart FX, Pasco S, Ramont L, Hornebeck W and Monboisse JC: An introduction to matrikines: extracellular matrix-derived peptides which regulate cell activity. Implication in tumour invasion. Crit Rev Oncol Hematol 49: 199-202, 2004.
11. Boutaud A, Borza DB, Bondar O, Gunwar S, Netzer KO, Singh N, Ninomiya Y, Sado Y, Noelken ME and Hudson BG: Type IV collagen of the glomerular basement membrane. Evidence that the chain specificity of network assembly is encoded by the noncollagenous NC1 domains. J Biol Chem 275: 30716-30724, 2000.
12. Chelberg MK, McCarthy JB, Skubitz AP, Furcht LT and Tsilibary EC: Characterization of a synthetic peptide from type IV collagen that promotes melanoma cell adhesion, spreading, and motility. J Cell Biol 111: 261-270, 1990.
13. Lauer-Fields JL, Malkar NB, Richet G, Drauz K and Fields GB: Melanoma cell CD44 interaction with the alpha 1 (IV) 1263-1277 region from basement membrane collagen is modulated by ligand glycosylation. J Biol Chem 278: 14321-14330, 2003.
14. Pasco S, Ramont L, Maquart FX and Monboisse JC: Control of melanoma progression by various matrikines from basement membrane macromolecules. Crit Rev Oncol Hematol 49: 221-233, 2004.
15. Breslow A: Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172: 902-908, 1970.
16. Ntayi C, Lorimier S, Berthier-Vergnes O, Hornebeck W and Bernard P: Cumulative influence of matrix metalloproteinase-1 and -2 in the migration of melanoma cells within three-dimensional type I collagen lattices. Exp Cell Res 270: 110-118, 2001.
17. Kurschat P, Zigrino P, Nischt R, Breitkopf K, Steurer P, Klein CE, Krieg T and Mauch C: Tissue inhibitor of matrix metalloproteinase-2 regulates matrix metalloproteinase-2 activation by modulation of membrane-type 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines. J Biol Chem 274: 21056-21062, 1999.
18. Hegerfeldt Y, Tusch M, Brocker EB and Friedl P: Collective cell movement in primary melanoma explants: plasticity of cell-cell interaction, beta1-integrin function, and migration strategies. Cancer Res 62: 2125-2130, 2002.
19. Pasquali-Ronchetti I, Baccarani-Contri M, Fornieri C, Mori G and Quaglino D: Structure and composition of the elastin fibre in normal and pathological conditions. Micron 24(1): 75-89, 1993.
20. Pasquali-Ronchetti I and Baccarani-Contri M: Elastic fiber during development and aging. Microsc Res Tech 38: 428-435, 1997.
21. Kielty CM, Sherratt MJ and Shuttleworth CA: Elastic fibres. J Cell Sci 115: 2817-2828, 2002.
22. Frances C and Robert L: Elastin and elastic fibres in normal and pathologic skin. Int J Dermatol 23: 166-179, 1984.
23. Rock MJ, Cain SA, Freeman LJ, Morgan A, Mellody K, Marson A, Shuttleworth CA, Weiss AS and Kielty CM: Molecular basis of elastic fiber formation. Critical interactions and a tropoelastin-fibrillin-1 cross-link. J Biol Chem 279: 23748-23758, 2004.
24. Trask BC, Trask TM, Broekelmann T and Mecham RP: The microfibrillar proteins MAGP-1 and fibrillin-1 form a ternary complex with the chondroitin sulfate proteoglycan decorin. Mol Biol Cell 11: 1499-1507, 2000.
25. Santra M, Reed CC and Iozzo RV: Decorin binds to a narrow region of the epidermal growth factor (EGF) receptor, partially overlapping but distinct from the EGF-binding epitope. J Biol Chem 277: 35671-35681, 2002.
26. Robert L and Hornebeck W (eds.): Elastin and Elastases. CRC Press (Boca Raton, Florida), Vol. 2, 1989.
27. Shinohara T, Suzuki K, Okada M, Shiigai M, Shimizu M, Maehara T and Ohsuzu F: Soluble elastin fragments in serum are elevated in acute aortic dissection. Arterioscler Thromb Vasc Biol 23: 1839-1844, 2003.
28. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP and Cheresh DA: Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85: 683-693, 1996.
29. DeClerck YA, Mercurio AM, Stack MS, Chapman HA, Zutter MM, Muschel RJ, Raz A, Matrisian LM, Sloane BF, Noel A, Hendrix MJ, Coussens L and Padarathsingh M: Proteases, extracellular matrix, and cancer. Am J Pathol 164: 1131-1139, 2004.
30. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002.
31. Mecham RP, Broekelmann TJ, Fliszar CJ, Shapiro SD, Welgus HG and Senior RM: Elastin degradation by matrix metalloproteinases. Cleavage site specificity and mechanisms of elastolysis. J Biol Chem 272: 18071-18076, 1997.
32. Hofmann UB, Westphal JR, Van Muijen GN and Ruiter DJ: Matrix metalloproteinases in human melanoma. J Invest Dermatol 115: 337-344, 2000.
33. Riedlinger G KS, Al-Housseini AM, Brow JM, Bugge TH, Leppla SH, Duesbery ND, Woude GV and Frankel A: Metastatic melanoma and matrix metalloproteinases. Drugs Future 28: 897-904, 2003.
34. Iida J, Wilhelmson KL, Price MA, Wilson CM, Pei D, Furcht LT and McCarthy JB: Membrane type-1 matrix metalloproteinase promotes human melanoma invasion and growth. J Invest Dermatol 122: 167-176, 2004.
35. Vaisanen A, Kallioinen M, Taskinen PJ and Turpeenniemi-Hujanen T: Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol 186: 51-58, 1998.
36. van den Oord JJ, Paemen L, Opdenakker G and de Wolf-Peeters C: Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol 151: 665-670, 1997.
37. Ntayi C, Labrousse AL, Debret R, Birembaut P, Bellon G, Antonicelli F, Hornebeck W and Bernard P: Elastin-derived peptides upregulate matrix metalloproteinase-2- mediated melanoma cell invasion through elastin-binding protein. J Invest Dermatol 122: 256-265, 2004.
38. Feinmesser M, Schachter JM, Tobar A, Sulkes J, Gutman H, Kruk N and Okon E: Relationship of tumourigcnic malignant melanomas to dermal elastin: an expression of tumour/stromal interaction that may be related to prognosis. Am J Dermatopathol 24: 108-117, 2002.
39. Blood CH, Sasse J, Brodt P and Zetter BR: Identification of a tumour cell receptor for VGVAPG, an elastin-derived chemotactic peptide. J Cell Biol 107: 1987-1993, 1988.
40. Kamoun A, Landeau JM, Godeau G, Wallach J, Duchesnay A, Pellat B and Hornebeck W: Growth Stimulation of human skin fibroblasts by elastin-derived peptides. Cell Adhes Commun 3: 273-281, 1995.
41. Timar J, Lapis K, Fulop T, Varga ZS, Tixier JM, Robert L and Hornebeck W: Interaction between elastin and tumour cell lines with different metastatic potential; in vitro and in vivo studies. J Cancer Res Clin Oncol 117: 232-238, 1991.
42. Timar J, Diczhazi C, Ladanyi A, Raso E, Hornebeck W, Robert L and Lapis K: Interaction of tumour cells with elastin and the metastatic phenotype. Ciba Found Symp 192: 321-335, 1995.
43. Hornebeck W, Tixier JM and Robert L: Inducible adhesion of mesenchymal cells to elastic fibres: elastonectin. Proc Natl Acad Sci USA 83: 5517-5520, 1986.
44. Svitkina TM and Parsons DF: Binding of some metastatic tumour cell lines to fibrous elastin and elastin peptides. Int J Cancer 53: 824-828, 1993.
45. Lapis K and Timar J: Role of elastin-matrix interactions in tumour progression. Semin Cancer Biol 12: 209-217, 2002.
46. Hinek A: Nature and the multiple functions of the 67-kD elastin-/laminin binding protein. Cell Adhes Commun 2:185-193, 1994.
47. Privitera S, Prody CA, Callahan JW and Hinek A: The 67-kDa enzymatically inactive alternatively spliced variant of beta-galactosidase is identical to the elastin/laminin-binding protein. J Biol Chem 273: 6319-6326, 1998.
48. Morreau H, Galjart NJ, Willemsen R, Gillemans N, Zhou XY and d'Azzo A: Human lysosomal protective protein. Glycosylation, intracellular transport, and association with beta-galactosidase in the endoplasmic reticulum. J Biol Chem 267: 17949-17956, 1992.
49. Lukong KE, Seyrantepe V, Landry K, Trudel S, Ahmad A, Gahl WA, Lefrancois S, Morales CR and Pshezhetsky AV: Intracellular distribution of lysosomal sialidase is controlled by the internalization signal in its cytoplasmic tail. J Biol Chem 276: 46172-46181, 2001.
50. Hinek A and Wilson SE: Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly. Am J Pathol 156: 925-938, 2000.
51. Jacob MP, Fulop T Jr, Foris G and Robert L: Effect of elastin peptides on ion fluxes in mononuclear cells, fibroblasts, and smooth muscle cells. Proc Natl Acad Sci USA 84: 995-999, 1987.
52. Duca L, Debelle L, Debret R, Antonicelli F, Hornebeck W and Haye B: The elastin peptides-mediated induction of pro-collagenase-1 production by human fibroblasts involves activation of MEK/ERK pathway via PKA- and PI(S)K-dependent signaling. FEBS Lett 524: 193-198, 2002.
53. Duca L, Lambert E, Debret R, Rothhut B, Blanchevoye C, Delacoux F, Hornebeck W, Martiny L and Debelle L: Elastin peptides activate ERK1/2 via a Ras-independent mechanism requiring both p110{gamma}/Raf-1 and PKA/B-Raf signaling in human skin fibroblasts. Mol Pharmacol 67: 1315-1324, 2005.
54. Mochizuki S, Brassart B and Hinek A: Signaling pathways transduced through the elastin receptor facilitate proliferation of arterial smooth muscle cells. J Biol Chem 277: 44854-44863, 2002.
55. Chen XP, Ding X and Daynes RA: Ganglioside control over IL-4 priming and cytokine production in activated T cells. Cytokine 12: 972-985, 2000.
56. Luttrell LM, Daaka Y and Lefkowitz RJ: Regulation of tyrosine kinase cascades by G-protein-coupled receptors. Curr Opin Cell Biol 11: 177-183, 1999.
57. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C and Ullrich A: EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402: 884-888, 1999.
58. Srivastava A, Laidler P, Davies RP, Horgan K and Hughes LE: The prognostic significance of tumour vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study. Am J Pathol 133: 419-423, 1988.
59. Toth-Jakatics R, Jimi S, Takebayashi S and Kawamoto N: Cutaneous malignant melanoma: correlation between neovascularization and peritumour accumulation of mast cells overexpressing vascular endothelial growth factor. Hum Pathol 31: 955-960, 2000.
60. Robinet A, Fahem A, Cauchard JH, Huet E, Vincent L, Lorimier S, Antonicelli F, Soria C, Crepin M, Hornebeck W and Bellon G: Elastin-derived peptides enhance angiogenesis by promoting endothelial cell migration and tubulogenesis through upregulation of MT1-MMP. J Cell Sci 118: 343-356, 2005.
61. Faury G, Usson Y, Robert-Nicoud M, Robert L and Verdetti J: Nuclear and cytoplasmic free calcium level changes induced by elastin peptides in human endothelial cells. Proc Natl Acad Sci USA 95: 2967-2972, 1998.
62. Hernandez-Barrantes S, Bernardo M, Toth M and Fridman R: Regulation of membrane type-matrix metalloproteinases. Semin Cancer Biol 12: 131-138, 2002.
63. Seiki M: Membrane-type 1 matrix metalloproteinase: a key enzyme for tumour invasion. Cancer Lett 194: 1-11, 2003.
64. Sabeh F, Ota I, Holmbeck K, Birkedal-Hansen H, Soloway P, Balbin M, Lopez-Otin C, Shapiro S, Inada M, Krane S, Allen E, Chung D and Weiss SJ: Tumour cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J Cell Biol 167: 769-781, 2004.
65. Chun TH, Sabeh F, Ota I, Murphy H, McDonagh KT, Holmbeck K, Birkedal-Hansen H, Allen ED and Weiss SJ: MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix. J Cell Biol 167: 757-767, 2004.
66. Huet E, Brassart B, Cauchard JH, Debelle L, Birembaut P, Wallach J, Emonard H, Polette M and Hornebeck W: Cumulative influence of elastin peptides and plasminogen on matrix metalloproteinase activation and type I collagen invasion by HT-1080 fibrosarcoma cells. Clin Exp Metastasis 19: 107-117, 2002.
67. Swindle CS, Tran KT, Johnson TD, Banerjee P, Mayes AM, Griffith L and Wells A: Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor. J Cell Biol 154: 459-468, 2001.
68. Califice S, Castronovo V and Van Den Brule F: Galectin-3 and cancer (Review). Int J Oncol 25: 983-992, 2004.
69. Liu FT and Rabinovich GA: Galectins as modulators of tumour progression. Nat Rev Cancer 5: 29-41, 2005.
70. Ochieng J, Warfield P, Green-Jarvis B and Fentie I. Galectin-3 regulates the adhesive interaction between breast carcinoma cells and elastin. J Cell Biochem 75: 505-514, 1999.
71. Ochieng J, Green B, Evans S, James O and Warfield P: Modulation of the biological functions of galectin-3 by matrix metalloproteinases. Biochim Biophys Acta 1379: 97-106, 1998.
72. Overall CM and Lopez-Otin C: Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2: 657-672, 2002.
73. Yusa T, Blood CH and Zetter BR: Tumour cell interactions with elastin: implications for pulmonary metastasis. Am Rev Respir Dis 140: 1458-1462, 1989.
74. 3 binds a unique non-RGD site near the C-terminus of human tropoelastin. Biochimie 86: 173-178, 2004.